Puma Biotechnology | PBYI - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Agios Pharmaceuticals USD 99.65M 13.95M 2026-06
Alnylam Pharmaceuticals USD 1.71B 2.46M 2026-06
Amgen USD 13.99B 1.95B 2026-06
Biogen USD 1.28B 2.1B 2026-06
BioMarin Pharmaceutical USD 874M 1.35B 2026-06
Daiichi Sankyo JPY 449.81B 92.35B 2026-03
Exelixis USD 281.45M 55.3M 2026-06
Gilead Sciences USD 7.63B 64M 2026-03
Glaxosmithkline GBP 3.44B 146M 2026-03
Incyte USD 3.98B 33.45M 2026-06
MacroGenics USD 113.91M 47.39M 2026-06
Moderna USD 1.72B 185M 2026-06
Novartis USD 7.62B 739M 2026-06
Pfizer USD 976M 727M 2026-06
PTC Therapeutics USD 1.05B 215.9M 2026-06
Puma Biotechnology USD 53.52M 1.14M 2025-09
Regeneron Pharmaceuticals USD 2.46B 506.8M 2026-06
Roche Holding CHF 7.55B 579M 2025-06
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sarepta Therapeutics USD 571.15M 106.7M 2026-06
Takeda JPY 460.98B 134.07B 2026-06
TG Therapeutics USD 612.25M 170.04M 2026-06
Ultragenyx Pharmaceutical USD 125M 50M 2026-06
Vanda Pharmaceuticals USD 84.85M 14.83M 2025-12
Vertex Pharmaceuticals USD 7.85B 605.7M 2026-06